Targeted Biotech Collaborations Potential partner opportunities with pharmaceutical and biotech firms pursuing GPCR, kinase, and cell signaling targets who require high-quality, endogenously expressed assay platforms to accelerate discovery and IND timelines.

SME Growth Potential Leverage Multispan’s mid-size company profile (11-50 employees) to position flexible collaboration models, fast pilots, and scalable services that align with CROs and biotech startups seeking rapid proof-of-concept in cardiovascular, metabolic, CNS, inflammation, immunology and oncology programs.

Quality and IP Advantage Highlight the breadth of GPCR-expressing cell lines and integrated screening solutions as a differentiator for customers requiring high-quality, reproducible data, potentially enabling premium pricing, longer-term partnerships, and expanded HTS/SAR services.

Expansion Readiness Identify sales angles around expanding assay capabilities to cover additional targets and primary/recombinant cells, offering a pathway for customers to scale from discovery through lead optimization and speed up IND readiness.

Funding and Collaboration Signals Capitalize on disclosed revenue and modest funding to approach venture-backed biotech and academia alliances seeking proven assay platforms with demonstrated collaborations and measurable impact on time-to-indication.